Innovative Fill-Finish Selkirk Pharma's state-of-the-art, purpose-built sterile manufacturing facility equipped with advanced fill/finish technologies, including ultra-high-yield fillers and isolator technology, presents opportunities for collaborations or supply agreements with biotech and pharma companies seeking reliable injectable product manufacturing.

Rapid Clinical Support The launch of ClinFAST™, a rapid fill/finish service tailored for clinical trial supplies, indicates a focus on supporting emerging biotech firms and clinical-stage companies needing quick turnaround and flexible manufacturing solutions.

Focused Market Expansion Recent investments of $60 million and facility expansions highlight Selkirk Pharma’s growth strategy, creating capacity for increased client intake—ideal for sales efforts targeting organizations looking for scalable, compliant manufacturing partners.

Regulatory-Ready Infrastructure With aseptic process simulation qualification and GMP compliance aligned with US FDA and EU regulations, Selkirk Pharma offers a validated, quality-focused production environment that appeals to companies prioritizing regulatory adherence and quality assurance.

Strong Funding & Leadership Recent seed funding of $24 million and leadership transition with a new CEO position Selkirk Pharma for aggressive growth, making it an attractive partner for investment or strategic collaborations in injectable drug manufacturing.